All Content Outsourced Pharma

  1. Do We Really Understand Plasmid Quality's Effects On mRNA Production? 5/1/2025

    Two experts examine the current guidelines and specs for plasmid DNA and question whether our understanding is sufficient.

  2. Commercializing RNAi Therapies With Alnylam's Tolga Tanguler 5/1/2025

    On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, and building therapeutic franchise "skyscrapers." Tanguler also shares his thoughts on commercializing RNAi therapies for larger patient populations, compared with rare disease populations, and reflects on changes in the biopharmaceutical sales and promotion model.

  3. The Serious Business Of Working With CDMOs At Phase 2 5/1/2025

    You might call Anthony Grenier, Sr Director CMC at Reunion Neuroscience, a "phase 2 outsourcing specialist." In his discussion with Chief Editor Louis Garguilo, he describes his experiences, and presents some key factors and advice for biotechs at that middle stage of working with CDMOs.

  4. Roquette Completes The Acquisition Of IFF Pharma Solutions 5/1/2025

    Roquette, a global leader in plant-based ingredients and pharmaceutical excipients for the health and nutrition sectors, announces the successful completion of its acquisition of IFF Pharma Solutions.

  5. SK pharmteco Opens New CGMP Plasmid Suite In King Of Prussia, Strengthening Commitment To Cell And Gene Therapy Innovation 5/1/2025

    SK pharmteco, a global contract development and manufacturing organization (CDMO), today announced the opening of its new Current Good Manufacturing Practice (CGMP) plasmid suite at its facility in King of Prussia, Pennsylvania.

  6. Using Virtual Reality To Enhance Aseptic Contamination Control 5/1/2025

    Technologies such as virtual reality (VR), augmented reality (AR), or mixed reality can help alleviate some of the long-standing issues in aseptic contamination control. Here's how.

  7. Part Of $1B Investment Strategy, PCI Pharma Services Completes Acquisition Of Ajinomoto Althea, Enhancing US Drug Product Manufacturing For Aseptic Filling Of Prefilled Syringes & Cartridges 5/1/2025

    PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – has completed its acquisition of Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and subsidiary of Japan-based Ajinomoto Co., Inc.

  8. AI Vs. Humans In Novel Drug Target Identification 4/30/2025

    Artificial intelligence is beginning to replace humans in drug discovery, one expert warns — but the industry isn’t ready for the shift.

  9. NorthX Biologics Receives CIR Accreditation To Support R&D Collaboration With French Biotech And Pharmaceutical Companies 4/30/2025

    NorthX Biologics, a leading biopharmaceutical CDMO, has been officially accredited by the French Ministry of Higher Education and Research for the Crédit d’Impôt Recherche (CIR) program for the years 2025-2026.

  10. Novartis To Acquire Regulus Therapeutics And Farabursen, An Investigational MicroRNA Inhibitor To Treat ADPKD, The Most Common Genetic Cause Of Renal Failure 4/30/2025

    Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded clinical-stage biopharmaceutical company focused on developing microRNA therapeutics.